Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?

Stefanie Knoll (), Christoph Mair (), Ursula Benter (), Katja Vouk () and Baudouin Standaert ()

Health Economics Review, 2013, vol. 3, issue 1, 1-11

Abstract: Routine rotavirus vaccination in Germany would reduce the number of hospitalised and outpatient cases. The associated investment could be fully offset by costs avoided in hospital stays, physician visits and SHI reimbursement of productivity losses. Sensitivity analysis indicated that vaccination would be cost-saving in 95% of simulations. Incremental cost was observed only under extreme conditions, especially when the time spent at home due to rotavirus disease was low or when vaccine efficacy against severe disease was heavily decreased. Copyright Knoll et al.; licensee Springer. 2013

Keywords: Cost savings; Economic evaluation; Germany; Paediatric; RIX4414; Rotavirus; Vaccination (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1186/2191-1991-3-27 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:3:y:2013:i:1:p:1-11:10.1186/2191-1991-3-27

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/2191-1991-3-27

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().